Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | PPARD | Q03181 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 4/20 | 0.44 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.43 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.43 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034300 | 0.90 | PPARG (0.45) | GAAMAPTPOLBPPARGPPARD | |
| SCHEMBL12670836 | 0.83 | GAA (0.69) | GAAMAPTPOLBPPARGPPARD | |
| SCHEMBL2030411 | 0.82 | MAPT (0.51) | GAAMAPTPOLBPPARGPPARD | |
| SCHEMBL2032790 | 0.82 | GAA (0.51) | GAAMAPTPOLBPPARGPPARD | |
| SCHEMBL2742720 | 0.80 | MAPT (0.51) | GAAMAPTPOLBPPARGPPARD | |
| SCHEMBL2032951 | 0.79 | PPARG (0.49) | GAAMAPTPOLBPPARGPPARD | |
| SCHEMBL2033513 | 0.78 | MAPT (0.46) | MAPTPPARAALDH1A1LMNAMEN1 | |
| SCHEMBL2035284 | 0.78 | GAA (0.47) | GAAMAPTPOLBPPARGPPARD | |
| SCHEMBL12670548 | 0.77 | MAPT (0.50) | GAAMAPTPOLBPPARGPPARD | |
| SCHEMBL2036273 | 0.77 | MAPT (0.47) | GAAMAPTPOLBPPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968567-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | AMGEN INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7626033-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | AMGEN INC. (US) | 2006-11-23 | — | — | US | disclosed |
| US-7041691-B1 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050250820-A1 | Therapeutic modulation of PPARgamma activity | AMGEN INC. (US) | 2005-11-10 | — | — | US | disclosed |
| US-20040248882-A1 | Noninsulin dependent diabetes, obesity, hypercholesterolemia, inflammatory disorders; reduced side effects; such as 5-(4-acetylbenzenesulfonamido-2-fluorophenoxy)-3-chloropyridine | TULARIK INC. | 2004-12-09 | — | — | US | disclosed |
| US-6770648-B2 | ANTIDIABETIC AGENTS | TULARIK INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030139390-A1 | Compounds for the modulation of PPARgamma activity | TULARIK INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1192137-A1 | COMPOUNDS FOR THE MODULATION OF PPAR$g(g) ACTIVITY | Tularik Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001000579-A1 | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY | TULARIK INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250820-A1 | Therapeutic modulation of PPARgamma activity | PPARG, PPARA, PPARD | GAA 1364/4885MAPT 708/4885POLB 690/4885 |
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | PPARG, PPARA, PPARD | GAA 1364/4885MAPT 708/4885POLB 690/4885 |
| US-20030139390-A1 | Compounds for the modulation of PPARgamma activity | PPARG, PPARA, PPARD | GAA 385/4885MAPT 4694/4885POLB 770/4885 |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | PPARG, PPARA, PPARD | GAA 402/4885MAPT 4679/4885POLB 743/4885 |
| US-20040248882-A1 | Noninsulin dependent diabetes, obesity, hypercholesterolemia, inflammatory disorders; reduced side effects; such as 5-(4-acetylbenzenesulfonamido-2-fluorophenoxy)-3-chloropyridine | PPARD, PPARG, PPARA | GAA 1483/4885MAPT 3839/4885POLB 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.